These in vitro and in vivo results indicate that under pathological conditions of DKD, GSK-3β expression and activity are up-regulated to induce HuR but inhibit TTP expression in podocytes, which leads to podocyte injury and inflammation thereby promoting the progression of DKD (Fig. 8). This evidence concerns the gene GSK3B and diabetic kidney disease.